Research & Development: Page 63

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    NEUROTHERAPEUTICS AND GENE AMPLIFICATION Markets Predicted to Grow Unmet need and ballooning incidence are expected to create huge market potential in neuro logical drugs,according to a study by Kalorama Infor mation. The world market stands at $70 billion, but steady growth in demand and product...

    By PharmaVoice Team • Jan. 13, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Pharma Outlet

    Fewer new drug approvals, the political spotlight on the pharmaceutical industry, promotional budget cutbacks. What else can go wrong in the healthcare communications industry? Pitted against their more endowed competitors, small agencies may be wellsuited to survive in today’s adverse environmen...

    By Rico Viray • Jan. 13, 2010
  • clinical trial diversity Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's on your mind: Opinions

    R&D will tell I am not sure that the mega company strategy/structure will support the trend toward biopharmaceutical products (and fur ther into the future, gene therapies) that offer therapeutic solutions for more specific diseases. The trend toward blockbuster product launches will give way...

    By PharmaVoice Team • Jan. 13, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    John T. Spitznagel — A New Horizon

    PharmaVOICE EARLY ON IN HIS CAREER,JOHN SPITZNAGEL SET HIS SIGHTS ON ONE DAY RUNNING A HEALTHCARE COMPANY. IN MAY 2002, AS CHAIRMAN AND CEO OF ESP PHARMA, HIS VISION BECAMEAREALITYONCEAGAIN. Mr. Spitznagel already has proven that he has what it takes to drive a company to success, having engineer...

    By Kim Ribbink • Jan. 11, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Finding a Spot for Frova

    Instead of trying to conquer the entire antimigraine market, Frova will stake its claim by focusing on a niche market segment that can benefit from the drug’s unique halflife and superior safety profile Frova isn’t the drug for every migraine patient. The marketers of the latest triptan to enter ...

    By Elisabeth Pena • Jan. 11, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Manufacturing for Bio Capacity

    George Coleman President, Biomedex Inc., Spokane, Wash.; Biomedex specializes in a broad spectrum of contract manufacturing services for bio- pharmaceutical clients, from regulatory compliance to aseptic filling, to validation, to cleanroom sanitizing agents, to quality assurance, to component cl...

    By Denise Myshko • Jan. 11, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    NEW HEALTHCARE RELATED PRODUCTS, SERVICES, AND COMPANIES Dorland Sweeney Jones Health Communications is reaffirming its position as a leader in global health communications and creating a power brand by simplifying its name and organizational structure. The agency has returned to its original nam...

    By PharmaVoice Team • Jan. 11, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Teams and effective practices that drive corporate growth. “Successful new product plan ning efforts realize that analytical teamstaffing efforts are essential to today’s blockbuster products,” says Paul Meade, VP at Best Prac tices. “Teams that have well rounded members who can bring a combinati...

    By PharmaVoice Team • Jan. 11, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Partners in Public Health

    The first influenza pandemic of the 21st century is under way. H1N1 influenza A has affected more than 207 countries and overseas territories worldwide, according the World Health Organization. As of the end of November 2009, 622,482 cases have been reported, including more than 7,820 deaths. In ...

    By Denise Myshko • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Executive Coaching

    The goal of coaching is the goal of good ­management: and that is to make the most of an organization’s valuable resources — ­Harvard Business Review he International Coach Federation (ICF), one of the largest worldwide resources for professional coaches, defines coaching as partnering with clien...

    By Taren Grom • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Dr. Thomas Steitz: The Right Chemistry

    Brilliance begets brilliance, and from early in his career, Thomas Steitz, Ph.D., has learned from and kept company with some of the most highly lauded scientific minds of the 20th and 21st centuries. Over the years, breakthrough discoveries regarding the ribosome have led to Dr. Steitz being oft...

    By Kim Ribbink • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Talent Pool

    Biotechnology POOL Dr. Diane JORKASKY Aileron Therapeutics Appoints Medical Chief Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, has appointed Diane Jorkasky, M.D., senior VP, head of development and chief medical of...

    By PharmaVoice Team • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    E-media

    E-upgrades and enhancements Prolifiq’s recent software release, Prolifiq for Life Sciences, is designed to help pharma, biotech, and medical-device companies comply with an increasingly complex web of regulations governing electronic sales communications. Constantly evolving guidelines, regulatio...

    By PharmaVoice Team • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    Oncology Performance Edge, Health Strategies Group’s recently launched strategic research service, helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources. “The oncology market is significantly different from others,...

    By PharmaVoice Team • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Most Americans Want More Info on New Biotechnologies Sidebars: What Do You Think Synthetic Biology Is? Rating the Best Drivers of Attendance to speaker events Pharma Rebranding of Speaker Events Is Paying Off Japan Prese...

    By PharmaVoice Team • Dec. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Year Ahead

    Looking back to the varying changes and pressures the industry has endured, and ahead to how the industry will need to reinvent itself to continue to prosper, companies are adapting to longer-term marketplace trends and evolving patient needs. The industry is facing pressure from the economic, re...

    By Denise Myshko and Robin Robinson • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Safety First Era

    The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process ...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    RNAI Technology

    Coming of Age: RNAi Technology As advances in genetics ­continue to improve our understanding of ­disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the n...

    By Denise Myshko • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Supply Chain Strategies

    Companies need to evaluate their business through their value streams rather than by individual processes or components. ccording to Bob Silvers, managing director, at SSA & Co., by applying the rigors of Lean Six Sigma to underperforming areas, pharmaceutical companies can completely transfo...

    By Denise Myshko • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Executive Suite

    Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. ...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    On the Calendar

    November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Index

    Julian Adams, Ph.D. President, Research and ­Development and Chief Scientific Officer, Infinity ­Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, ­International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Service Consolidation Recommended for Clinical trial Offices Emerging centralized clinical trial offices (CTOs) are among the newest developments within the research administration infrastructure of academic health centers. Little uniformity exists in the structure or functions of existing CTOs, ...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    buster brands,”says David Lipson,forecasting practice leader at IMS Global Consulting.“But we are not see ing the avalanche that some feared. Although the number of major new product launches was smaller than usual last year, the genuine value provided by medicines introduced over the past dozen ...

    By PharmaVoice Team • Nov. 3, 2009